Please login to the form below

Not currently logged in
Email:
Password:

Takeda UK launches new Prostap format

Takeda has launched a simpler, more efficient presentation of its prostate cancer and endometriosis treatment

Takeda UK has launched its prostate cancer and endometriosis and uterine fibroids treatment Prostap DCS (leuprorelin acetate) in a dual chamber pre-filled syringe.

The company said that the latest syringe offers a simplified, intuitive and efficient delivery system compared to the original Prostap vial and syringe mechanism.

Raj Persad, consultant urologist, Bristol Royal Infirmary and Southmead Hospital commented "Leuprorelin acetate has proved to be an efficacious treatment for prostate cancer for many years. An accurate and user-friendly delivery system can only be a positive step forward, particularly as administration is more efficient and therefore saves time. This can result in a better standard of care for patients as more time is spent providing much needed support and advice."

Prostap DCS delivers the same active ingredient and will be available in the same doses as existing presentations: one-month Prostap SR DCS (depot injection 3.75mg) and three-month Prostap 3 DCS (depot injection 11.25mg).

Prostap will not be available after October 2011.

6th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics